H
|
| H1 receptor antagonists |
|
 |
| for angioedema |
|
 |
| for cholinergic reactions |
|
 |
| for hives |
|
 |
| prescribing information for allergic rhinitis or conjunctivitis (Table) |
|
 |
| prescribing information for nausea and vomiting (Table) |
|
 |
|
| H2 receptor antagonists |
|
 |
| for hives |
|
 |
| prescribing information for GERD (Table) |
|
 |
| prescribing information for H pylori-induced ulcerations (Table) |
|
 |
| for stress-ulcer prevention |
|
 |
|
| Habitrol (transdermal nicotine patch) (Table) |
|
 |
|
| Haemophilus influenzae |
|
 |
| in community-acquired pneumonia |
|
 |
| COPD therapy (Table) |
|
 |
| in nursing-homeacquired pneumonia |
|
 |
|
| Halcinonide (Halog) (Table) |
|
 |
|
| Haldol |
|
 |
| See also Haloperidol |
|
 |
| prescribing information for agitation (Table) |
|
 |
| prescribing information for delirium |
|
 |
| prescribing information for nausea and vomiting |
|
 |
| prescribing information for psychosis (Table) |
|
 |
|
| Halitosis |
|
 |
|
| Hallucinations |
|
 |
|
| Halobetasol propionate (Ultravate) (Table) |
|
 |
|
| Halog (halcinonide) (Table) |
|
 |
|
| Haloperidol (Haldol) |
|
 |
| daily dose thresholds (Table) |
|
 |
| drug and metabolic interactions (Table) |
|
 |
| prescribing information for agitation (Table) |
|
 |
| prescribing information for delirium |
|
 |
| prescribing information for nausea and vomiting (Table) |
|
 |
| prescribing information for nausea and vomiting at end of life |
|
 |
| prescribing information for psychosis (Table) |
|
 |
|
| Harris-Benedict energy requirement equations |
|
 |
|
| Hazardous drinking |
|
 |
|
| HCTZ (hydrochlorothiazide) (Esidrix, HydroDIURIL, Oretic) |
|
 |
| antihypertensive combinations (Table) |
|
 |
| prescribing information for HTN (Table) |
|
 |
|
| HDL (high-density lipoprotein) |
|
 |
| in diabetes |
|
 |
| in subacute MI |
|
 |
|
| Headache (Table) |
|
 |
|
| Health care proxy |
|
 |
|
| Health Shake |
|
 |
|
| Hearing aids |
|
 |
|
| Hearing impairment |
|
 |
| Hearing Impairment chapter |
|
 |
| effects and rehabilitation (Table) |
|
 |
| and falls (Table) |
|
 |
| resources for |
|
 |
| screening (Table) |
|
 |
|
| Heart disease |
|
 |
| See also Cardiovascular diseases |
|
 |
| anticoagulation in absence of active bleeding or severe bleeding risk (Table) |
|
 |
| determinants for hospice eligibility (Table) |
|
 |
| end-stage (Table) |
|
 |
| ICD placement for |
|
 |
| prevention in women |
|
 |
| resources for |
|
 |
| valvular (Table) |
|
 |
|
| Heart failure (HF) |
|
 |
| Heart Failure section |
|
 |
| anticoagulation for (Table) |
|
 |
| antihypertensive therapy and (Table) |
|
 |
| drugs useful in treating (Table) |
|
 |
| ICD placement for |
|
 |
| staging (Table) |
|
 |
| target doses of ACE inhibitors and ARBs (Table) |
|
 |
|
| Heat therapy |
|
 |
| for osteoarthritis |
|
 |
| for pain management |
|
 |
|
| Heel inserts |
|
 |
|
| Heel pain |
|
 |
|
| Heel protectors |
|
 |
| for arterial ulcers |
|
 |
| for pressure ulcers |
|
 |
|
| Helicobacter pylori infection |
|
 |
| FDA-approved treatments (Table) |
|
 |
| peptic ulcer disease |
|
 |
|
| Helidac |
|
 |
| See also Tetracycline |
|
 |
| prescribing information for H pylori-induced ulcerations (Table) |
|
 |
|
| Hematologic disorders |
|
 |
|
| Hemiparesis (Table) |
|
 |
|
| Hemiplegia (Table) |
|
 |
|
| Hemodialysis |
|
 |
|
| Hemolytic anemia |
|
 |
|
| Hemorrhagic stroke |
|
 |
|
| Heparin (Hep-Lock) |
|
 |
| See also Anticoagulation |
|
 |
| for DVT/PE prophylaxis and treatment |
|
 |
| LMWH |
|
 |
| for DVT/PE prophylaxis and treatment |
|
 |
| for PE |
|
 |
| prescribing information for DVT or PE prophylaxis and treatment |
|
 |
| before surgery |
|
 |
| and osteoporosis |
|
 |
| for PE |
|
 |
| prescribing information for acute coronary syndrome (Table) |
|
 |
| prescribing information for DVT or PE prophylaxis and treatment (Table) |
|
 |
| before surgery |
|
 |
| UFH |
|
 |
| for DVT/PE prophylaxis and treatment |
|
 |
| for PE |
|
 |
| prescribing information for DVT or PE prophylaxis and treatment (Table) |
|
 |
| before surgery |
|
 |
|
| Heparin-induced thrombocytopenia (Table) |
|
 |
|
| Heparinoids (Table) |
|
 |
|
| Hepatitis B vaccines |
|
 |
|
| Hep-Lock |
|
 |
| See also Heparin |
|
 |
| prescribing information for acute coronary syndrome (Table) |
|
 |
| prescribing information for DVT or PE prophylaxis and treatment (Table) |
|
 |
|
| Herbal medications (Table) |
|
 |
|
| Herpes zoster ("shingles") |
|
 |
| Herpes Zoster ("shingles") section |
|
 |
| antiviral treatments (Table) |
|
 |
| postherpetic neuralgia |
|
 |
|
| Hexadrol |
|
 |
| See also Dexamethasone |
|
 |
| prescribing information for adrenal insufficiency (Table) |
|
 |
|
| HF (heart failure) |
|
 |
| Heart Failure section |
|
 |
| anticoagulation for (Table) |
|
 |
| antihypertensive therapy and (Table) |
|
 |
| drugs useful in treating (Table) |
|
 |
| ICD placement for |
|
 |
| staging (Table) |
|
 |
| target doses of ACE inhibitors and ARBs (Table) |
|
 |
|
| High-density lipoprotein (HDL) |
|
 |
| in diabetes |
|
 |
| in MI after acute management |
|
 |
|
| High-fiber diet |
|
 |
|
| Hip fracture |
|
 |
| Hip Fracture section |
|
 |
| medications for osteoporosis and (Table) |
|
 |
|
| Hip fracture surgery |
|
 |
| anticoagulation for DVT or PE prophylaxis and treatment (Table) |
|
 |
| anticoagulation in absence of active bleeding or severe bleeding risk (Table) |
|
 |
| hip fracture treatment |
|
 |
|
| Hip padding (Table) |
|
 |
|
| Hip pain |
|
 |
|
| Hip protectors |
|
 |
|
| Hip replacement |
|
 |
| anticoagulation for DVT or PE prophylaxis and treatment |
|
 |
| anticoagulation in absence of active bleeding or severe bleeding risk (Table) |
|
 |
| for hip fracture |
|
 |
| for osteoarthritis |
|
 |
|
| Histrelin acetate (Vantas) (Table) |
|
 |
|
| Histussin HC (hydrocodone + phenylephrine + chlorpheniramine) (Table) |
|
 |
|
| Hives |
|
 |
|
| HMG-CoA (Table) |
|
 |
|
| HMG-CoA reductase inhibitors (Table) |
|
 |
|
| Home BP monitoring |
|
 |
|
| Home safety evaluation (Table) |
|
 |
|
| Homocysteinemia |
|
 |
|
| Hormone receptor agonists (Table) |
|
 |
|
| Hormone therapy |
|
 |
| Hormone Therapy section |
|
 |
| for anorexia, cachexia, dehydration |
|
 |
| for breast cancer |
|
 |
| for dyspareunia |
|
 |
| estrogen therapy |
|
 |
| Estrogen Therapy section |
|
 |
| bone outcomes (Table) |
|
 |
| effects on other outcomes, level of evidence, and risks (Table) |
|
 |
| GnRH agonists |
|
 |
| prescribing information for prostate cancer |
|
 |
| for prostate cancer |
|
 |
| for osteoporosis prevention |
|
 |
| for osteoporosis treatment |
|
 |
| for prostate cancer |
|
 |
| regimens (Table) |
|
 |
| risks and benefits (Table) |
|
 |
| for sleep disorders (Table) |
|
 |
| for UI |
|
 |
|
| Hospice |
|
 |
| Hospice Referral section |
|
 |
| determinants for hospice (Table) |
|
 |
| resources for |
|
 |
| sites of posthospital care (Table) |
|
 |
|
| Hospital-acquired pneumonia |
|
 |
| empiric antibiotic therapy |
|
 |
| expected organisms |
|
 |
|
| Hot flushes |
|
 |
| medications for osteoporosis and (Table) |
|
 |
| postmenopausal |
|
 |
|
| Housing alternatives |
|
 |
|
| HTN (hypertension) |
|
 |
| Hypertension section |
|
 |
| combination drugs for (Table) |
|
 |
| in diabetes mellitus type 2 |
|
 |
| post MI |
|
 |
|
| Humabid LA |
|
 |
| See also Guaifenesin |
|
 |
| prescribing information for COPD (Table) |
|
 |
|
| Humalog (insulin lispro) (Table) |
|
 |
|
| Humira (adalimumab) |
|
 |
|
| Humorsol (demecarium) (Table) |
|
 |
|
| Humulin |
|
 |
| See also Insulin |
|
 |
| preparations (Table) |
|
 |
|
| Hyalgan (hyaluronic acid) |
|
 |
|
| Hyaluronic acid |
|
 |
| for osteoarthritis (Table) |
|
 |
| prescribing information for knee osteoarthritis |
|
 |
|
| Hycodan (hydrocodone) (Table) |
|
 |
|
| Hydralazine (Apresoline) |
|
 |
| for HF |
|
 |
| isosorbide dinitrate and hydralazine (BiDil) |
|
 |
| for HF |
|
 |
| for HTN (Table) |
|
 |
| prescribing information for HF |
|
 |
| prescribing information for HTN (Table) |
|
 |
|
| Hydration |
|
 |
| See also Dehydration |
|
 |
| for bowel obstruction |
|
 |
| for pressure ulcers |
|
 |
|
| Hydrochlorothiazide. See HCTZ |
|
 |
|
| Hydrocodone (Hycodan) |
|
 |
| with APAP (Lorcet, Lortab, Vicodin) |
|
 |
| for pain management |
|
 |
| prescribing information for pain (Table) |
|
 |
| with ASA (Lortab ASA) (Table) |
|
 |
| with ibuprofen (Vicoprofen) (Table) |
|
 |
| with phenylephrine and chlorpheniramine (Histussin HC) (Table) |
|
 |
| prescribing information for cough (Table) |
|
 |
|
| Hydrocolloids (Comfeel, DuoDERM, extra thin film DuoDERM, Nu-derm, RepliCare, Tegasorb) |
|
 |
| prescribing information for pressure ulcers (Table) |
|
 |
| wound and pressure ulcer products (Table) |
|
 |
|
| Hydrocortisone (Cortef, Hydrocortone) |
|
 |
| prescribing information for adrenal insufficiency (Table) |
|
 |
| prescribing information for adrenal insufficiency management |
|
 |
| prescribing information for adrenal insufficiency therapy |
|
 |
| prescribing information for intertrigo |
|
 |
| prescribing information for seborrheic dermatitis |
|
 |
| prescribing information for xerosis |
|
 |
| for prostate cancer |
|
 |
| for squamous hyperplasia |
|
 |
|
| Hydrocortisone acetate (Hytone) (Table) |
|
 |
|
| Hydrocortisone butyrate (Locoid) (Table) |
|
 |
|
| Hydrocortisone valerate (Westcort) (Table) |
|
 |
|
| Hydrocortone |
|
 |
| See also Hydrocortisone |
|
 |
| prescribing information for adrenal insufficiency (Table) |
|
 |
|
| HydroDIURIL (HCTZ) (Table) |
|
 |
|
| Hydrogel |
|
 |
| amorphous gels (IntraSite gel, Restore gel, SoloSite gel) (Table) |
|
 |
| gel sheets (Restore Impregnated Gauze, Vigilon) (Table) |
|
 |
| for skin ulcers |
|
 |
| wound and pressure ulcer products (Table) |
|
 |
|
| Hydromorphone (Dilaudid, Hydrostat) |
|
 |
| initial dosing for PCA (Table) |
|
 |
| prescribing information for pain (Table) |
|
 |
|
| Hydropres (reserpine with HCTZ) (Table) |
|
 |
|
| Hydrostat |
|
 |
| See also Hydromorphone |
|
 |
| prescribing information for pain (Table) |
|
 |
|
| Hydroxychloroquine |
|
 |
| digoxin interactions |
|
 |
| ocular adverse events |
|
 |
| prescribing information for rheumatoid arthritis |
|
 |
|
| Hydroxyurea |
|
 |
|
| Hydroxyzine (Atarax) |
|
 |
| daily dose thresholds (Table) |
|
 |
| and dementia |
|
 |
| prescribing information for allergic rhinitis or conjunctivitis (Table) |
|
 |
|
| Hygroton (chlorthalidone) (Table) |
|
 |
|
| Hyoscyamine (Anaspaz, Levsin, Levsin/SL) |
|
 |
| prescribing information for IBS |
|
 |
| prescribing information for spasm, pain, and vomiting |
|
 |
|
| Hypercalcemia (Table) |
|
 |
|
| Hyperemia, conjunctival |
|
 |
|
| Hyperglycemia |
|
 |
| differential diagnosis |
|
 |
| and hyponatremia |
|
 |
| and pneumonia |
|
 |
|
| Hyperkalemia |
|
 |
| Hyperkalemia section |
|
 |
| and chronic kidney failure |
|
 |
|
| Hyperlipidemia. See Dyslipidemia |
|
 |
|
| Hypernatremia |
|
 |
|
| Hyperparathyroidism, secondary |
|
 |
|
| Hyperphosphatemia |
|
 |
|
| Hypersomnolence |
|
 |
|
| Hypertension (HTN) |
|
 |
| Hypertension section |
|
 |
| combination drugs for (Table) |
|
 |
| in diabetes mellitus type 2 |
|
 |
| post MI |
|
 |
|
| Hyperthyroidism |
|
 |
| Hyperthyroidism section |
|
 |
| antihypertensive therapy and (Table) |
|
 |
| differential diagnosis |
|
 |
|
| Hypertonic sodium gain |
|
 |
|
| Hyperuricemia |
|
 |
|
| Hypnosis |
|
 |
| for IBS |
|
 |
| for pain management |
|
 |
| for sleep disorders other than sleep apnea |
|
 |
|
| Hypnotics |
|
 |
|